Streetbeat News

Stock Prices

CLOV

Clover Health shares are trading higher following the purchase of 877,567 shares by a company director.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:40 am

PFE

SRPT

The FDA has approved the expanded use of Sarepta Therapeutics' (NASDAQ:SRPT) gene therapy Elevidys for Duchenne muscular dystrophy (DMD) to include both ambulatory and non-ambulatory patients aged 4 and above. Sarepta will conduct a confirmatory trial for non-ambulatory patients. The news follows disappointing results from Pfizer's (NYSE:PFE) Phase 3 study for a similar treatment.

Portfolio Pulse from Vandana Singh

June 21, 2024 | 11:39 am

CLNN

Clene presented preliminary data for CNM-Au8 as a potential treatment for Rett Syndrome at the International Rett Syndrome Foundation 2024 Annual Meeting. CNM-Au8 targets energy metabolism in nervous system cells to enhance neuronal survival and function.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:13 am

HTZ

Hertz has announced the upsize and pricing of its $1 billion offerings, with the closure expected on or about June 28, 2024, subject to customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:10 am

HTZ

Hertz has announced the upsize and pricing of its $1 billion offerings. The company plans to use the net proceeds to pay down a portion of its $2 billion committed revolving credit facility, which will improve its liquidity.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:09 am

OCGN

Ocugen has received approval from the Data and Safety Monitoring Board (DSMB) to enroll patients in the high dose cohort 3 of its Gardian study for Stargardt disease. The medium dose has been established as safe and tolerable in the ongoing OCU410ST clinical trial.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:05 am

FDS

FactSet has revised its fiscal year 2024 guidance, lowering its revenue expectations to $2.18B-$2.19B from $2.20B-$2.21B, while raising its adjusted EPS forecast to $16.00-$16.40 from $15.60-$16.00. The company also adjusted its organic ASV growth and operating margin expectations.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:05 am

DIA

NVDA

QQQ

SPY

UUP

Global markets experienced mixed performance with U.S. stock markets closing mixed, Asian markets mostly declining, and European markets also down. The U.S. Dollar strengthened due to a relatively hawkish Federal Reserve stance despite weak housing and labor market data.

Portfolio Pulse from Akanksha Bakshi

June 21, 2024 | 10:55 am

KMX

CarMax (NYSE:KMX) reported Q1 earnings per share (EPS) of $0.97, beating the analyst estimate of $0.94. However, sales of $7.11 billion missed the $7.21 billion estimate. Both EPS and sales showed a decline compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 10:52 am

MCHP

VTI

XLK

Microchip Technology (NASDAQ:MCHP) stock saw a recovery on Friday after a selloff on Thursday. The company announced that its JAN transistors are now qualified for Military-Standard Enhanced Low Dose Radiation Sensitivity (ELDRS) requirements. Microchip has a strong legacy in aerospace and defense, with dedicated facilities in Ennis, Ireland, and Lawrence, Massachusetts. Analysts expect a rebound in the analog industry. MCHP shares traded higher by 2.00% at $90.80 premarket on Friday. Investors can also gain exposure through Vanguard Total Stock Market ETF (NYSE:VTI) and SPDR Select Sector Fund – Technology (NYSE:XLK).

Portfolio Pulse from Anusuya Lahiri

June 21, 2024 | 10:52 am